February 29, 2024
Every week, a global community of Fatty Liver Disease stakeholders comes together to explore the most important challenges in diagnosing, treating, and developing medications for patients with Fatty Liver Diseases.
Join hepatology researcher and Key Opinion Leader Dr. Stephen Harrison, liver wellness advocate Louise Campbell MSc AP., Forecasting and Pricing guru Roger Green, M.B.A., and their weekly guests as they discuss these issues from their own unique perspectives on the Surfing the NASH Tsunami podcast.
Global NASH Council Chair Zobair Younossi joins the Surfers to discuss his recent review article on MASLD epidemiology and what stakeholders can do to help stem the tsunami of new patients.
The first episode of Season 5 of Surfing the MASH Tsunami starts with a brief discussion of what the co-hosts have worked on for the last two months and proceeds to consider the impact on patient treatment of having a MASH drug approved in the US market, particularly in today’s direct-to-consumer weight loss advertising.
Surfing the MASH Tsunami continues its 2023 wrap-up conversations with Ukraine Public Health Executive Tatiana Deshko, Mike Betel of the Fatty Liver Alliance and co-host Roger Green.
Surfing the MASH Tsunami continues its 2023 wrap-up conversations with Novo Nordisk International Medical Vice President Michelle Long, along with co-hosts Louise Campbell and Roger Green.
Surfing the MASH Tsunami continues its 2023 wrap-up conversations with biotech entrepreneur Rachel Zayas, Founder and CEO of AGED Diagnostics, along with co-hosts Louise Campbell and Roger Green.
Global Liver Institute Founder and CEO Donna Cryer joins Louise Campbell and Roger Green to discuss her personal challenges during the last part of 2023, the growing strength of the Global Liver Institute and the challenges facing GLI and the entire community in 2024.
Patient advocates Neeraj Mistry of the Fatty Liver Foundation and Jenn Leigh Jones of the Society for Sober Liver Survival join Louise Campbell and Roger Green to discuss the merging of their organizations and the impact of the new nomenclature on how patients might look at their disease.